União Europeia - português - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - atosiban (as acetate) - nascimento prematuro - outros gynecologicals - atosiban é indicado ao atraso iminente do pre-termo de nascimento, durante a gravidez em mulheres adultas com:contrações uterinas regulares de no mínimo 30 segundos de duração, a uma taxa de ≥ 4 por 30 minutos, uma dilatação cervical de 1 a 3 cm (0-3 para nulliparas) e apagamento de ≥ 50%;uma idade gestacional de 24 de até 33 semanas completas;um normal de frequência cardíaca fetal.

União Europeia - português - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - temozolomida - glioma; glioblastoma - agentes antineoplásicos - temozolomide sol é indicado para o tratamento de:pacientes adultos diagnosticados com glioblastoma multiforme concomitante com a radioterapia (rt) e, subsequentemente, em monoterapia do tratamento;crianças a partir de três anos de idade, adolescentes e pacientes adultos com glioma maligno, tal como glioblastoma multiforme ou astrocitoma anaplásico, mostrando recorrência ou progressão após a terapia padrão.

União Europeia - português - EMA (European Medicines Agency)

zambon spa - metanossulfonato de safinamida - doença de parkinson - anti-parkinson - xadago está indicado para o tratamento de pacientes adultos com doença de parkinson idiopática (pd) como terapia complementar a uma dose estável de levodopa (l-dopa) isoladamente ou em combinação com outros medicamentos para pd em pacientes variáveis ​​de fase média a tardia.

União Europeia - português - EMA (European Medicines Agency)

almirall s.a - fumarato de dimetilo - psoríase - imunossupressores - skilarence é indicado para o tratamento da psoríase em placas moderada a grave em adultos com necessidade de terapia medicamentosa sistêmica.

União Europeia - português - EMA (European Medicines Agency)

almirall s.a - tildrakizumab - psoríase - imunosupressão, interleucina inibidores, - ilumetri é indicado para o tratamento de adultos com moderada para severa psoríase em placas que são candidatos à terapia sistêmica,.

União Europeia - português - EMA (European Medicines Agency)

almirall, s.a. - tirbanibulin - queratose, actinic - antibióticos e quimioterápicos para uso dermatológico - klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (olsen grade 1) of the face or scalp in adults.

União Europeia - português - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tipo 2 - drogas usadas em diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

União Europeia - português - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenem de sódio - infecções bacterianas - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 e 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. deve ser tido em consideração a orientação oficial sobre o uso apropriado de agentes antibacterianos..

União Europeia - português - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatida - osteoporosis; osteoporosis, postmenopausal - homeostase de cálcio - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

União Europeia - português - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas em diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triplo terapia de combinação), como adjuvante da dieta e exercício em pacientes inadequadamente controlados em sua máxima tolerada, a dose de metformina e uma sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.